AI-based cfDNA fragmentome liquid biopsy can detect early liver fibrosis, cirrhosis, and indicate broader chronic disease signals.
Key Details
- 1Johns Hopkins team applied AI and genome-wide cfDNA fragmentation analysis to diagnose early liver fibrosis and cirrhosis.
- 2Study analyzed samples from 1,576 people with liver disease and comorbidities using whole-genome sequencing.
- 3AI algorithms identified disease-specific fragmentation patterns, enabling high sensitivity detection of early liver disease.
- 4Current clinical tests often miss early fibrosis and only detect cirrhosis around 50% of the time.
- 5Prototype assay also signaled risk for other chronic diseases, such as cardiovascular and inflammatory conditions.
- 6Technology builds upon earlier cancer fragmentome studies, focusing now on non-cancer chronic conditions.
Why It Matters
Early detection of liver fibrosis is critical because it is reversible at early stages, potentially preventing progression to cirrhosis and cancer. This AI-enabled cfDNA approach could expand the role of noninvasive liquid biopsy in radiological diagnostics and broader chronic disease management.
Source
EurekAlert
Related News
•EurekAlert
New VIS-Fb Nanobody Probes Transform High-Precision Cellular Imaging
Salk and Einstein researchers have developed visible-spectrum antigen-stabilizable fluorescent nanobodies (VIS-Fbs) for sharper, multi-color live-cell imaging with minimal background noise.
•EurekAlert
NIH-Backed AI Model Predicts Cancer Survival Using Single-Cell Data
Researchers have developed scSurvival, a machine learning tool that uses single-cell tumor data to accurately predict cancer patient survival and identify high-risk cell populations.
•EurekAlert
Deep Learning Pathomics Platform Improves Immunotherapy Prediction in Lung Cancer
A deep learning pathomics platform accurately predicts immunotherapy response in metastatic NSCLC using routine pathology slides.